Investors seeking a more defensive positioning have rushed into health care stocks in recent months, as hype about the aging bull market, big tech misses, and troubles in emerging markets hit the tape. Still, the pharma sector faces stiff headwinds in the form of pending state and federal legislation, slower drug price inflation, and rising competition . . .

To read more, sign up for aFree 30-Day Trial   of MRP's research, orLog In